active
ACTIVE SINCE: 2017

AMR Industry Alliance

The AMR Industry Alliance is one of the largest private sector coalitions set up to provide sustainable solutions to curb antimicrobial resistance, with over 100 biotech, diagnostics, generics and research-based pharmaceutical companies and associations joining forces.
SGDS CONTRIBUTING TO:
SHOW SUB-TARGETS + HIDE SUB-TARGETS -
Pharma (non-IFPMA member) 14
Professional and Trade Associations 10
Life Sciences 12
Technology 44
Generic Manufacturers 5
Academia or research institute 1
Hospitals Health Facilities 1
Objectives

The AMR Industry Alliance aims to contribute sustainable solutions to curb antimicrobial resistance by creating a broad industry momentum and facilitating collaboration between the public and private sectors.

The life sciences industries are a crucial partner in efforts to curb AMR. Within this context, the AMR Industry Alliance (AMRIA) was established in 2017 and brings together leading biopharmaceutical, biotechnology, diagnostic, generics companies and industry associations to address AMR-related issues.

The principles of the AMR Industry Alliance are based on its two founding documents: the Davos Declaration and the Industry Roadmap. Since then, Alliance commitments have evolved in line with industry progress and global priorities.

The Alliance measures and drives the life-sciences industry progress to curb antimicrobial resistance in four different areas: research and science, appropriate use, access, manufacturing.

RESEARCH & SCIENCE 

  • Invest in research and development for innovative antibiotics and antibiotic dosage forms, vaccines, new technologies, and diagnostics.
  • Continue to advocate for policies that support sustainable investment in AMR-relevant innovation.
  • Partner with policymakers, payers, and other relevant stakeholders on new reimbursement, valuation, and commercial models that support appropriate patient access and a sustainable supply of antibiotics and AMR-relevant vaccines and new technologies and diagnostics.
  • Support collaboration and sharing of relevant non-proprietary data with different stakeholders (e.g., academia, consortia, small or medium-sized enterprise (SMEs), public researchers and industry) to help address key scientific and public health challenges.

ACCESS 

  • Address barriers to patient access to the most appropriate treatment, vaccine, or diagnostic.
  • Work in collaboration with policymakers to create an economic and regulatory environment that enables the sustainable supply of quality-assured antibiotics.
  • Work to reduce the prevalence of substandard and falsified AMR-relevant products.

APPROPRIATE USE 

  • Contribute to slowing the emergence of resistance by preventing infections by promoting vaccination and reduction of inappropriate use of antibiotics through expanded use of diagnostics.
  • Support appropriate use of antibiotics by working closely with other partners on awareness campaigns, continued education for healthcare professionals, and generation of evidence to support appropriate use and stewardships.
  • Collect and share surveillance data with public health bodies and healthcare professionals to improve understanding of resistance trends, monitor the effectiveness of antibiotics, inform appropriate antibiotic and vaccine use, and develop adapted infection control strategies.
  • Ensure that any promotional activities for antibiotics are aligned with the goal of advancing stewardship.

MANUFACTURING AND ENVIRONMENT 

  • Review Alliance member’s own manufacturing and supply chains to assess good practice in controlling release of antibiotics into the environment.
  • Establish a common framework for managing antibiotic discharge, and start to apply it across their own manufacturing and supply chains by 2018.
  • Work with stakeholders to develop a practical mechanism transparently show that Alliance member supply chains meet the frameworks standards.
  • Work with independent technical experts to establish science-driven, risk-based targets for discharge concentrations of antibiotics and develop good practice methods to reduce environmental impacts of manufacturing discharges by 2020.
Results and milestones
  • The AMR Industry Alliance’s Progress Report reflects on collective achievements from the life sciences industry to minimize the spread of antimicrobial resistance (AMR). The progress reports can be accessed here.
  • The AMR Industry Alliance has been driving responsible manufacturing of antibiotics. This has been a step-wise approach, first with the establishment of science-based predicted no-effect concentration (PNECs) targets, helping minimize antibiotic resistance and environmental toxicity. Another major milestone was achieved in 2018, with Alliance members agreeing on a framework that promotes responsible antibiotic manufacturing. In June 2022, the Alliance took this work one step further and published its Antibiotic Manufacturing Standard: “Minimizing risk of developing antibiotic resistance and aquatic ecotoxicity in the environment resulting from the manufacturing of human antibiotics”. The Standard, facilitated by BSI Standards Limited (BSI), provides clear guidance to manufacturers in the global antibiotic supply chain to ensure that their antibiotics are made responsibly. More details can be found here.
  • The AMR Industry Alliance has established an annual Stewardship Prize, to acknowledge organizations in low- and middle-income countries who use innovative approaches to AMR stewardship in their communities, with the goal of helping these organizations further scale their promising practices. More information about the Prize can be found here.
Geographic Reach
  • Global Commitment
Disease Area
  • Infectious and Parasitic Disease
See Disease Areas
Partner organizations
Pharma (non-IFPMA member)

Viatris

LOCUS Biosciences

MicuRx

Pheerecydes Pharma

Taxis Pharmaceuticals

TetraPhase Pharmaceuticals

vitas Pharma

Xellia Pharmaceuticals

Paratek

Athalone Laboratories

Blueberry Therapeutics

Clarametyx Biosciences

Destiny Pharma

FEDORA Pharmaceuticals

Professional and Trade Associations

Vereniging Innovatieve Geneesmiddelen

British In Vitro Diagnostic Association (BIVDA)

Medicines for Europe

Association for Accessible Medicines (AAM)

Biotechnology Industry Organization (BIO)

Advanced medical Technology Association (AdvaMed)

Antimicrobial Innovation Alliance

BEAM Alliance

British Generic Manufacturers Association

UK BioIndustry Association

Life Sciences

MeMed

MOBIDING

NEMIS Technologies

Northern Antibiotics

Quantum MD

Spectromics

Agile Sciences

AiCuris

Biomerieux

Cepheid

Curetis

HemoCue

Technology

BIOVERSYS

NovaBiotics

UNION Therapeutics

Bugworks

NovaDigm Therapeutics

Venatorx

Combioxin

OJBIO

VibioSphen

ContraFect

Peptilogics

CURZA

Phare Bio

ELIGO BIoscience

PHICO Therapeutics

FASTinov

POLYPHOR

BD (Becton Dickinson)

FORGE Therapeutics

Rebiotix

ABAC Therapeutics

HELPERBY

SCYNEXIS

Aequor

iNtRON Biotechnology

SetLance

Allecra Therapeutics

meiji

SinSa Labs

Alphanosos

Microbion Corporation

SOLIGENIX

Amplyx

Melinta Therapeutics

SPERO Therapeutics

ANTABIO

Mutabilis

SPEXIS

AntibioTx

Nabriva Therapeutics

Summit Therapeutics

AUROBAC Therapeutics

Nosopharm

Synthetic Genomics

Generic Manufacturers

Aurobindo Pharma Ltd

Centrient Pharmaceuticals

Frasenius Kabi

Recipharm

Venus

Academia or research institute

IMMT

Hospitals Health Facilities

Oragenics

Additional resources